Agile Therapeutics (NASDAQ:AGRX) Given a $3.00 Price Target by Maxim Group Analysts

Maxim Group set a $3.00 price objective on Agile Therapeutics (NASDAQ:AGRX) in a research note issued to investors on Friday morning, TipRanks reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered Agile Therapeutics from a strong-buy rating to a hold rating in a research note on Tuesday, October 8th. ValuEngine lowered Agile Therapeutics from a sell rating to a strong sell rating in a research note on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Buy and an average target price of $3.45.

Shares of AGRX opened at $1.16 on Friday. The firm has a market cap of $50.60 million, a PE ratio of -2.00 and a beta of 0.38. The firm has a fifty day simple moving average of $1.19 and a two-hundred day simple moving average of $1.30. Agile Therapeutics has a 1-year low of $0.53 and a 1-year high of $1.70.

Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Research analysts expect that Agile Therapeutics will post -0.37 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Acadian Asset Management LLC increased its stake in shares of Agile Therapeutics by 7.9% in the 2nd quarter. Acadian Asset Management LLC now owns 450,180 shares of the specialty pharmaceutical company’s stock worth $657,000 after purchasing an additional 32,911 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Agile Therapeutics by 5.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock worth $3,291,000 after buying an additional 120,403 shares during the period. JPMorgan Chase & Co. boosted its holdings in Agile Therapeutics by 2,219.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock worth $108,000 after buying an additional 73,238 shares during the period. BlackRock Inc. boosted its holdings in Agile Therapeutics by 27.2% in the 2nd quarter. BlackRock Inc. now owns 169,226 shares of the specialty pharmaceutical company’s stock worth $247,000 after buying an additional 36,212 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Agile Therapeutics by 129.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock worth $2,530,000 after buying an additional 978,672 shares during the period. Hedge funds and other institutional investors own 43.73% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Recommended Story: What does earnings per share mean?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.